Lazard Asset Management
KITE

Lazard Asset Management’s Kite Pharma, Inc. KITE Stock Holding History

Lazard Asset Management’s Portfolio KITE Stock Details KITE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-6,267
Closed -$361K – 1238
2014
Q4 		$361K Buy
+6,267
New +$264K ﹤0.01% 857

Other funds holding KITE

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WCM
Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
SFM
Soros Fund Management New York $9.12B AUM 30.69% 1-Year Est. Return

Lazard Asset Management's KITE Position: Q1 2015 in Review

Lazard Asset Management sold out of Kite Pharma, Inc. (KITE) in Q1 2015, closing a stake of 6,267 shares — an estimated $361K sold.

Lazard Asset Management first reported a position in KITE in Q4 2014 and held it in 1 quarter. The position peaked at $361K in Q4 2014. 148 funds tracked by Wall St. Rank hold KITE as of Q1 2015.

  • Lazard Asset Management reported no remaining Kite Pharma, Inc. position as of Q1 2015 after selling out during the quarter.
  • Lazard Asset Management sold 6,267 Kite Pharma, Inc. shares in Q1 2015, an estimated $361K.
  • Lazard Asset Management first reported a position in Kite Pharma, Inc. in Q4 2014 and held it in 1 quarter.
  • Lazard Asset Management's Kite Pharma, Inc. position peaked at $361K in Q4 2014.
  • 148 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q1 2015.

Based on Lazard Asset Management's 13F filing for Q1 2015, filed 15 May 2015.